

Joanne Chiu

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9852167/publications.pdf>

Version: 2024-02-01

32
papers

743
citations

840119

11
h-index

610482

24
g-index

33
all docs

33
docs citations

33
times ranked

1138
citing authors

#	ARTICLE	IF	CITATIONS
1	Pembrolizumab (Keytruda). <i>Human Vaccines and Immunotherapeutics</i> , 2016, 12, 2777-2789.	1.4	237
2	Ipilimumab and nivolumab/pembrolizumab in advanced hepatocellular carcinoma refractory to prior immune checkpoint inhibitors. , 2021, 9, e001945.		74
3	The use of single-agent sorafenib in the treatment of advanced hepatocellular carcinoma patients with underlying Child-Pugh B liver cirrhosis. <i>Cancer</i> , 2012, 118, 5293-5301.	2.0	65
4	The Outcomes and Safety of Single-Agent Sorafenib in the Treatment of Elderly Patients with Advanced Hepatocellular Carcinoma (HCC). <i>Oncologist</i> , 2011, 16, 1721-1728.	1.9	63
5	Integrating Molecular Mechanisms and Clinical Evidence in the Management of Trastuzumab Resistant or Refractory HER-2+ Metastatic Breast Cancer. <i>Oncologist</i> , 2011, 16, 1535-1546.	1.9	50
6	Complications of traditional Chinese/herbal medicines (TCM) – a guide for perplexed oncologists and other cancer caregivers. <i>Supportive Care in Cancer</i> , 2009, 17, 231-240.	1.0	44
7	Is There a Role for Unstimulated Thyroglobulin Velocity in Predicting Recurrence in Papillary Thyroid Carcinoma Patients with Detectable Thyroglobulin after Radioiodine Ablation?. <i>Annals of Surgical Oncology</i> , 2012, 19, 3479-3485.	0.7	38
8	Recent Advances and Future Prospects in Immune Checkpoint (ICI)-Based Combination Therapy for Advanced HCC. <i>Cancers</i> , 2021, 13, 1949.	1.7	31
9	Coexisting ductal carcinoma in situ independently predicts lower tumor aggressiveness in node-positive luminal breast cancer. <i>Medical Oncology</i> , 2012, 29, 1536-1542.	1.2	17
10	Nivolumab + Ipilimumab for patients with hepatocellular carcinoma previously treated with Sorafenib. <i>Expert Review of Gastroenterology and Hepatology</i> , 2021, 15, 589-598.	1.4	17
11	Efficacy and Tolerability of Adjuvant Oral Capecitabine plus Intravenous Oxaliplatin (XELOX) in Asian Patients with Colorectal Cancer: 4-Year Analysis. <i>Asian Pacific Journal of Cancer Prevention</i> , 2013, 14, 6585-6590.	0.5	16
12	The real-world use of regorafenib for metastatic colorectal cancer: multicentre analysis of treatment pattern and outcomes in Hong Kong. <i>Postgraduate Medical Journal</i> , 2017, 93, 395-400.	0.9	13
13	A phase 1 study of pegylated recombinant arginase (PEG-BCT-100) in combination with systemic chemotherapy (capecitabine and oxaliplatin) [PACOX] in advanced hepatocellular carcinoma patients. <i>Investigational New Drugs</i> , 2022, 40, 314-321.	1.2	11
14	Advanced Pancreatic Cancer: Flourishing Novel Approaches in the Era of Biological Therapy. <i>Oncologist</i> , 2014, 19, 937-950.	1.9	9
15	Thyroid Immune-Related Adverse Events in Patients with Cancer Treated with anti-PD1/anti-CTLA4 Immune Checkpoint Inhibitor Combination: Clinical Course and Outcomes. <i>Endocrine Practice</i> , 2021, 27, 886-893.	1.1	9
16	The Use of Cabozantinib in Advanced Hepatocellular Carcinoma in Hong Kong – A Territory-Wide Cohort Study. <i>Cancers</i> , 2021, 13, 2002.	1.7	8
17	Metastatic Pancreatic Cancer: Are We Making Progress in Treatment?. <i>Gastroenterology Research and Practice</i> , 2012, 2012, 1-6.	0.7	7
18	The Outcomes of Systemic Treatment in Recurrent Hepatocellular Carcinomas Following Liver Transplants. <i>Advances in Therapy</i> , 2021, 38, 3900-3910.	1.3	7

#	ARTICLE	IF	CITATIONS
19	Outcomes of tyrosine kinase inhibitors (TKI) after immunotherapy in unresectable or advanced hepatocellular carcinoma (HCC) patients.. Journal of Clinical Oncology, 2019, 37, 361-361.	0.8	5
20	Advances in the Systemic Treatment of Neuroendocrine Tumors in the Era of Molecular Therapy. Anti-Cancer Agents in Medicinal Chemistry, 2013, 13, 382-388.	0.9	5
21	BioPATH: A Biomarker Study in Asian Patients with HER2+ Advanced Breast Cancer Treated with Lapatinib and Other Anti-HER2 Therapy. Cancer Research and Treatment, 2019, 51, 1527-1539.	1.3	5
22	A Phase I, Single- and Multiple-dose Study to Evaluate the Pharmacokinetics of Elbasvir and Grazoprevir in Healthy Chinese Participants. Clinical Therapeutics, 2018, 40, 719-732.e1.	1.1	4
23	Changing pattern of recurrences in patients with early HER2-positive breast cancer receiving neoadjuvant chemotherapy in the era of dual anti-HER2 therapy. Postgraduate Medical Journal, 2019, 95, 155-161.	0.9	3
24	Randomized phase II trial of sorafenib, capecitabine and oxaliplatin (SECOX) versus single agent sorafenib in patients with advanced hepatocellular carcinoma.. Journal of Clinical Oncology, 2019, 37, 365-365.	0.8	3
25	Editorial to "Palbociclib and letrozole in advanced breast cancer". Translational Cancer Research, 2017, 6, S376-S379.	0.4	2
26	Opportunities to improve clinical trial design in urothelial bladder cancer. Clinical Research and Regulatory Affairs, 2015, 32, 61-69.	2.1	0
27	What determines treatment success and future perspectives?. Postgraduate Medical Journal, 2016, 92, 123-124.	0.9	0
28	Safety and tolerability of subcutaneous trastuzumab and intravenous pertuzumab as adjuvant treatment for HER2 positive breast cancer: a pilot study. Postgraduate Medical Journal, 2021, , postgradmedj-2021-140319.	0.9	0
29	Neoadjuvant Therapy with Concurrent Docetaxel, Epirubicin, and Cyclophosphamide (TEC) in High-Risk HER2-Negative Breast Cancers. Advances in Therapy, 2021, 38, 5752-5762.	1.3	0
30	Efficacy and safety of capecitabine, oxaliplatin, and irinotecan (xeloxiri) as salvage therapy for patients with treatment-refractory metastatic colorectal cancer: A prospective, open-label, phase II study.. Journal of Clinical Oncology, 2014, 32, e14511-e14511.	0.8	0
31	A phase II study of capecitabine, oxaliplatin and irinotecan (XELOXIRI) as salvage therapy in patients with refractory metastatic colorectal cancer.. Journal of Clinical Oncology, 2017, 35, e15049-e15049.	0.8	0
32	Sorafenib plus doxorubicin in advanced hepatocellular carcinoma patients: hope or hype?. Annals of Translational Medicine, 2020, 8, 1695-1695.	0.7	0